These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

294 related articles for article (PubMed ID: 35102468)

  • 21. Novel combinatorial strategies for boosting the efficacy of immune checkpoint inhibitors in advanced breast cancers.
    Tolba MF; Elghazaly H; Bousoik E; Elmazar MMA; Tolaney SM
    Clin Transl Oncol; 2021 Oct; 23(10):1979-1994. PubMed ID: 33871826
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The application of immune checkpoint blockade in breast cancer and the emerging role of nanoparticle.
    Masoumi E; Tahaghoghi-Hajghorbani S; Jafarzadeh L; Sanaei MJ; Pourbagheri-Sigaroodi A; Bashash D
    J Control Release; 2021 Dec; 340():168-187. PubMed ID: 34743998
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Updates in combined approaches of radiotherapy and immune checkpoint inhibitors for the treatment of breast cancer.
    Jungles KM; Holcomb EA; Pearson AN; Jungles KR; Bishop CR; Pierce LJ; Green MD; Speers CW
    Front Oncol; 2022; 12():1022542. PubMed ID: 36387071
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A review of immune checkpoint blockade in breast cancer.
    Pellegrino B; Tommasi C; Cursio OE; Musolino A; Migliori E; De Silva P; Senevirathne TH; Schena M; Scartozzi M; Farci D; Willard-Gallo K; Solinas C
    Semin Oncol; 2021 Jun; 48(3):208-225. PubMed ID: 34620502
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PD-L1 status in breast cancer: Current view and perspectives.
    Vranic S; Cyprian FS; Gatalica Z; Palazzo J
    Semin Cancer Biol; 2021 Jul; 72():146-154. PubMed ID: 31883913
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new biological triangle in cancer: intestinal microbiota, immune checkpoint inhibitors and antibiotics.
    Zhang J; Dai Z; Yan C; Zhang W; Wang D; Tang D
    Clin Transl Oncol; 2021 Dec; 23(12):2415-2430. PubMed ID: 34125407
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Towards the era of immune checkpoint inhibitors and personalized cancer immunotherapy.
    Nakajima H; Nakatsura T
    Immunol Med; 2021 Mar; 44(1):10-15. PubMed ID: 32643578
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer.
    Matusz-Fisher A; Tan AR
    Expert Opin Biol Ther; 2022 Mar; 22(3):385-395. PubMed ID: 34806498
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The future of microfluidics in immune checkpoint blockade.
    Briones J; Espulgar W; Koyama S; Takamatsu H; Tamiya E; Saito M
    Cancer Gene Ther; 2021 Sep; 28(9):895-910. PubMed ID: 33110208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Landscape of adenosine pathway and immune checkpoint dual blockade in NSCLC: progress in basic research and clinical application.
    Wang R; Liu Z; Wang T; Zhang J; Liu J; Zhou Q
    Front Immunol; 2024; 15():1320244. PubMed ID: 38348050
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immune Checkpoint Inhibitors and Novel Immunotherapy Approaches for Breast Cancer.
    Cejuela M; Vethencourt A; Pernas S
    Curr Oncol Rep; 2022 Dec; 24(12):1801-1819. PubMed ID: 36255603
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Combination Strategies for Immune-Checkpoint Blockade and Response Prediction by Artificial Intelligence.
    Huemer F; Leisch M; Geisberger R; Melchardt T; Rinnerthaler G; Zaborsky N; Greil R
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32325898
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Immune Checkpoint Blockade in Patients with Triple-Negative Breast Cancer.
    Michel LL; von Au A; Mavratzas A; Smetanay K; Schütz F; Schneeweiss A
    Target Oncol; 2020 Aug; 15(4):415-428. PubMed ID: 32514907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Patients' experiences of cancer immunotherapy with immune checkpoint inhibitors: A systematic review and thematic synthesis.
    Watts T; Roche D; Csontos J
    J Clin Nurs; 2024 Aug; 33(8):2885-2904. PubMed ID: 38589992
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Single peptides and combination modalities for triple negative breast cancer.
    Razazan A; Behravan J
    J Cell Physiol; 2020 May; 235(5):4089-4108. PubMed ID: 31642059
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DUX4 is a common driver of immune evasion and immunotherapy failure in metastatic cancers.
    Pineda JMB; Bradley RK
    Elife; 2024 Jun; 12():. PubMed ID: 38829686
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
    Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
    Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
    Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cancer immunotherapy with immune checkpoint inhibitors and infections: A particular focus on mycobacterial infections.
    Fujita K; Elkington PT
    Respir Investig; 2024 May; 62(3):339-347. PubMed ID: 38417355
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of checkpoint inhibitors in advanced non-small cell lung cancer at population level from the National Immunotherapy Registry.
    Smit HJM; Aerts J; van den Heuvel M; Hiltermann TJN; Bahce I; Smit EF; Dingemans AC; Hendriks LE; Stigt JA; Schramel FMNH; van Tinteren H; Groen HJM;
    Lung Cancer; 2020 Feb; 140():107-112. PubMed ID: 31911323
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.